Unlocking the Next Level of Ultrasensitivity with Enhanced Variants

Natera has recently integrated Foresight’s phased-variant technology into the Signatera™ platform, combining ultrasensitive detection below 0.1 ppm with Natera’s market-leading commercial and operational infrastructure for MRD testing. This enhanced version of Signatera™ is offered alongside CLARITY™ and Latitude™, supporting tumor-informed and tissue-free MRD applications.

This Engager session will explore how incorporating additional variant classes enables the next level of ultrasensitivity and creates new opportunities for MRD-guided clinical trials.

Speakers:

Eser Kirkizlar

Sr Director of Bioinformatics

Natera

John Simmons

PhD - Global VP, Biopharma Partnerships

Natera

Jeffrey Gregg

MD - VP Medical Affairs

Foresight

David Kurtz

MD, PhD – Chief Medical Officer, Head of Research, and Co-Founder

Foresight

Dejan Knezevic

PhD - Sr. Director, Biopharma Partnerships

Natera

Sandra Close

Chief Operating Officer

Foresight, now part of Natera